{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07365241","nct_id":"NCT07365241","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07365241. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive ABBV-706 as part of the 53 month study duration.","label":"ABBV-706","type":"EXPERIMENTAL"},{"description":"Participants will receive SOC (topotecan, lurbinectedin, and amrubicin) as part of the 53 month study duration.","label":"Stand of Care (SOC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-09","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":531,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ABBV-706","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin","otherNames":[],"type":"DRUG"},{"name":"Amrubicin","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"AbbVie","official_title":"A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 24 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 28 months"}],"references":[],"start_date":{"date":"2026-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT07365241"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07365241"}